EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Symptom Network Dynamics during Antipsychotic Treatment in First-Episode Psychosis

Melissa G Zandstra iD, Floortje E Scheepers, Gabriela Lunansky iD, Silvana Galderisi, Birte Y Glenthøj, Inge Winter-van Rossum, Metten Somers, Edwin van Dellen

Schizophrenia Bulletin · 07.03.2026 · 52 (2)

DOI: 10.1093/schbul/sbag016 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 21.03.2026. Verfasst von Melissa G Zandstra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders, Olanzapine, Amisulpride. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission Seventh Framework Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis: Treatment response in first-episode psychosis varies substantially, yet underlying factors remain poorly understood. Symptom network theory suggests that inter-symptom relationships may influence treatment response. We hypothesized that symptom networks at baseline, as well as dynamic interactions over time, would differ between remitters and non-remitters, and that specific antipsychotics would show differential symptom-targeting effects. Study Design: We compared baseline and temporal symptom networks between remitters (n = 250) and non-remitters (n = 196) from the OPTiMiSE trial using 21-item Positive and Negative Syndrome Scale (PANSS) data. Baseline networks were estimated using Gaussian graphical models and compared with the Network Comparison Test. Temporal networks across baseline, week 2, and week 4 were modeled using Cross-Lagged Panel Network analysis. Key symptoms were identified by in- and out-prediction values. Group differences were assessed via non-zero edge weight correlations and Jaccard Index (JI). Network Intervention Analysis was used to examine differential effects of continuing amisulpride versus switching to olanzapine in non-responders (n = 85). Study Results: Baseline networks did not differ between outcome groups. However, temporal networks showed substantial differences: remitters and non-remitters had minimal overlap in symptom connections (baseline→week 2: JI = 0.014; week 2 → week 4: JI = 0.055) and virtually no correlation in connection strengths (baseline→week 2: r = -0.089, P = .447; week 2 → week 4: r = 0.005, P = .968). Key nodes (highest in/out-prediction) differed between groups. No robust symptom-specific medication effects emerged. Conclusions: Temporal symptom dynamics, rather than static baseline relationships, differentiate response trajectories and could inform future research on early markers of non-remission. Absence of antipsychotic-specific effects suggests generic treatment mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsPsychotic DisordersOlanzapineAmisulprideSchizophreniaOutcome Assessment, Health CareHumansFemaleMaleAdultTreatment Effect HeterogeneityYoung AdultAdolescent

Stichwörter der Autor:innen

Cross-Lagged Panel Network modelamisulpridenetwork intervention analysisolanzapinetreatment response

Substanzen

Antipsychotic AgentsOlanzapineAmisulpride

Autor:innen und Institutionen

  • Department of Psychiatry, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.
  • Department of Epidemiology and Data Science, Amsterdam University Medical Centers, VUMC, Amsterdam, 1081 BT, The Netherlands.
  • Department of Mental and Physical Health and Preventive Medicine, University of Campania, Luigi Vanvitelli, Naples, 81100, Italy.
  • Center for Neuropsychiatric Schizophrenia Research (CNSR) and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Copenhagen University Hospital, Mental Health Center Glostrup, Glostrup,…
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark.
  • Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York, 10029, United States.

ORCID-Profile: Melissa G Zandstra, Gabriela Lunansky

Förderung

  • European Commission Seventh Framework Program

Zitieren

APA

Zandstra, M. G., Scheepers, F. E., Lunansky, G., Galderisi, S., Glenthøj, B. Y., Winter-van Rossum, I., Somers, M., & van Dellen, E. (2026). Symptom Network Dynamics during Antipsychotic Treatment in First-Episode Psychosis. Schizophrenia Bulletin, 52(2). https://doi.org/10.1093/schbul/sbag016

Vancouver

Zandstra MG, Scheepers FE, Lunansky G, Galderisi S, Glenthøj BY, Winter-van Rossum I, et al. Symptom Network Dynamics during Antipsychotic Treatment in First-Episode Psychosis. Schizophrenia Bulletin. 2026;52(2). doi:10.1093/schbul/sbag016

BibTeX
@article{Zandstra2026,
  author = {Zandstra, Melissa G and Scheepers, Floortje E and Lunansky, Gabriela and Galderisi, Silvana and Glenthøj, Birte Y and Winter-van Rossum, Inge and Somers, Metten and van Dellen, Edwin},
  title = {Symptom Network Dynamics during Antipsychotic Treatment in First-Episode Psychosis},
  journal = {Schizophrenia Bulletin},
  year = {2026},
  volume = {52},
  number = {2},
  doi = {10.1093/schbul/sbag016}
}
Kostenlos starten →